ASCO 2010 - Erweiterung der standards durch molekulare therapien? Ein kongressbericht der 46.jahrestagung der American society of clinical oncology, Chicago 4-8.6.2010

Medicine and Dentistry

• Bevacizumab 100%
• Ovarian Cancer 50%
• Immunohistochemistry 50%
• Cervical Cancer 50%
• Progression Free Survival 50%
• Breast Cancer 50%
• Meta-Analysis 50%
• Receptor 50%
• Uterine Cancer 50%
• Elderly Patient 50%
• Capecitabine 50%
• Female Genital Tract Cancer 50%
• Gemcitabine 50%
• Intraoperative Radiation Therapy 50%
• Recurrent Ovarian Cancer 50%
• Sunitinib 50%
• Docetaxel 50%
• Carboplatin 50%